Opioids in breast cancer: Between analgesia and modulation of tumour progression
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun +2 more
wiley +1 more source
Investigating radiotherapy's impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab. [PDF]
He WM, Li WS.
europepmc +1 more source
The J‐TAIL‐2 prospective, observational study evaluated atezolizumab combined with several chemotherapy regimens in patients with advanced/metastatic non‐small cell lung cancer in routine clinical practice in Japan. The real‐world efficacy and safety of each atezolizumab combination were found to be comparable to those seen in the relevant global ...
Hiroshige Yoshioka +19 more
wiley +1 more source
Analysis of microvascular density differences in advanced ovarian cancer after neoadjuvant chemotherapy with or without bevacizumab in real world. [PDF]
Qi L +5 more
europepmc +1 more source
SPP1 was identified as a key driver of intratumoral fibrosis and hepatocellular carcinoma (HCC) progression through transcriptomic, histological, and functional analyses. Mechanistically, SPP1 promotes HSC activation and fibrosis via the SPP1–CD44–GLI1 axis, and pharmacologic inhibition of Hedgehog signaling effectively reduces tumor growth and ...
Atsushi Nara +16 more
wiley +1 more source
We conducted an in vivo genome‐wide CRISPR‐Cas9 knockout screen using MTMCT‐derived cells to identify genes essential for tumor growth. SOD1 emerged as a key therapeutic target, and its inhibition suppressed tumor proliferation by disrupting redox homeostasis, both in vitro and in PDX models. ABSTRACT Malignant transformation of mature cystic teratoma (
Satoshi Tamauchi +8 more
wiley +1 more source
Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion. [PDF]
Huang JP, Tsai CK, Hsieh PY, Chen SC.
europepmc +1 more source
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study [PDF]
Carlo Signorelli +30 more
openalex +1 more source
Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases [PDF]
Émilie Le Rhun +5 more
openalex +1 more source

